Bausch + Lomb Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance

Global eye health company Bausch + Lomb Corporation reported third-quarter 2026 financial results, generating $1.375 billion in total revenue, a 7 percent increase from $1.281 billion in Q3 2025. Excluding unfavorable foreign exchange impacts of $6 million, constant currency revenue rose approximately 8 percent. Growth occurred across all three segments: Vision Care increased 5 percent (6 percent constant currency), Surgical grew 9 percent, and Pharmaceuticals rose 11 percent. Key drivers included daily SiHy contact lenses, Lumify, premium IOLs, and Miebo. Operating income reached $155 million, up from $95 million the prior year. The company raised its full-year 2026 revenue guidance to $5.45–$5.55 billion from $5.44–$5.54 billion.